128 results on '"Maini, Brijeshwar"'
Search Results
102. Feasibility of Transcatheter Mitral Valve Repair for Non-A2P2 Mitral Regurgitation.
- Author
-
Lodhi, Hamza A., Mathews, Adithya, Bansal, Priya, Altaii, Haider, Morcos, Ramez, Desai, Anand, Maini, Brijeshwar, and Khalili, Houman
- Published
- 2021
103. Intra-Atrial Mass–Thrombus Versus Myxoma, Post-Amplatzer Atrial Septal Defect Closure Device Deployment
- Author
-
Gupta, Nidhi, primary, Abdelsalam, Murad, additional, Maini, Brijeshwar, additional, Mumtaz, Mubashir, additional, and Mandak, Jeffrey, additional
- Published
- 2012
- Full Text
- View/download PDF
104. COST-EFFECTIVENESS OF IMPELLA HEMODYNAMIC SUPPORT IN THE EMERGENT CARE PATIENT GROUP
- Author
-
Maini, Brijeshwar Singh, primary, Buyantseva, Larisa, additional, Popma, Jeffrey, additional, acquaviva, kate, additional, gregory, david, additional, and oneill, William, additional
- Published
- 2012
- Full Text
- View/download PDF
105. IN VIVO LIPID CORE PLAQUE BURDEN AND SPATIAL DISTRIBUTION IN PATIENTS WITH UNSTABLE ANGINA AND NQMI: A NEAR-INFRARED SPECTROSCOPY STUDY
- Author
-
Maini, Brijeshwar Singh, primary, Kini, Annapoorna, additional, Virmani, Renu, additional, Sharma, Samin, additional, and Narula, Jagat, additional
- Published
- 2012
- Full Text
- View/download PDF
106. COST-EFFECTIVENESS AND QUALITY OF LIFE IMPROVEMENTS: IMPELLA HEMODYNAMIC SUPPORT COMPARED WITH INTRA- AORTIC BALLOON PUMP IN HIGH RISK PATIENTS RECEIVING PCI
- Author
-
Maini, Brijeshwar Singh, primary, O'Neill, William, additional, Palacios, Igor, additional, Dixon, Simon, additional, and Gregory, David, additional
- Published
- 2012
- Full Text
- View/download PDF
107. IMPELLA IMPROVES CLINICAL OUTCOMES WHEN EXTENSIVE REVASCULARIZATION IS PERFORMED: THE PROTECT II STUDY
- Author
-
Popma, Jeffrey J., primary, Moses, Jeffrey, additional, Kleiman, Neal, additional, Almonacid, Alexandra, additional, Burke, David, additional, Dixon, Simon, additional, Maini, Brijeshwar, additional, Mulukutla, Suresh, additional, Henriques, José, additional, Dzavik, Vladimir, additional, Ohman, Erik, additional, and O'Neill, William, additional
- Published
- 2012
- Full Text
- View/download PDF
108. Detection of Lipid-Core Plaques by Intracoronary Near-Infrared Spectroscopy Identifies High Risk of Periprocedural Myocardial Infarction
- Author
-
Goldstein, James A., primary, Maini, Brijeshwar, additional, Dixon, Simon R., additional, Brilakis, Emmanouil S., additional, Grines, Cindy L., additional, Rizik, David G., additional, Powers, Eric R., additional, Steinberg, Daniel H., additional, Shunk, Kendrick A., additional, Weisz, Giora, additional, Moreno, Pedro R., additional, Kini, Annapoorna, additional, Sharma, Samin K., additional, Hendricks, Michael J., additional, Sum, Steve T., additional, Madden, Sean P., additional, Muller, James E., additional, Stone, Gregg W., additional, and Kern, Morton J., additional
- Published
- 2011
- Full Text
- View/download PDF
109. INTRACORONARY LIPID BURDEN AT BIFURCATIONS: RESULTS FROM THE COLOR REGISTRY
- Author
-
Townsend, Jacob, primary, Steinberg, Daniel H., additional, Nielsen, Christopher D., additional, Todoran, Thomas M., additional, Zwerner, Peter L., additional, McCarty, Christopher P., additional, McManus, William J., additional, Sneed, J. Darrell, additional, Patel, Chetan P., additional, Leonardi, Robert A., additional, Brilakis, Emmanouil S., additional, Shunk, Kendrick A., additional, Goldstein, James A., additional, Kern, Morton J., additional, Maini, Brijeshwar, additional, and Powers, Eric R., additional
- Published
- 2011
- Full Text
- View/download PDF
110. ASSOCIATION OF LARGE LIPID CORE PLAQUE DETECTED BY NEAR INFRARED SPECTROSCOPY WITH POST PERCUTANEOUS CORONARY INTERVENTION MYOCARDIAL INFARCTION
- Author
-
Maini, Brijeshwar, primary, Brilakis, Emmanouil S., additional, Kim, Michael, additional, Hendricks, Michael J., additional, Sum, Stephen T., additional, Madden, Sean P., additional, Muller, James E., additional, Rizik, David, additional, and Dixon, Simon R., additional
- Published
- 2010
- Full Text
- View/download PDF
111. Clinical Coronary Chemograms and Lipid Core Containing Coronary Plaques
- Author
-
Maini, Brijeshwar, primary
- Published
- 2008
- Full Text
- View/download PDF
112. Real-Time Three Dimensional Intracardiac Echocardiography: An Early Single-Center Experience.
- Author
-
Maini, Brijeshwar
- Published
- 2015
113. The Current Use of Impella 2.5 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the USpella Registry.
- Author
-
O'NEILL, WILLIAM W., SCHREIBER, THEODORE, WOHNS, DAVID H. W., RIHAL, CHARANJIT, NAIDU, SRIHARI S., CIVITELLO, ANDREW B., DIXON, SIMON R., MASSARO, JOSEPH M., MAINI, BRIJESHWAR, and OHMAN, E. MAGNUS
- Subjects
CARDIOGENIC shock ,HEALTH outcome assessment ,MECHANICAL properties of the heart ,HEMODYNAMICS ,MYOCARDIAL revascularization ,CONFIDENCE intervals ,PATIENTS - Abstract
Objectives To evaluate the periprocedural characteristics and outcomes of patients supported with Impella 2.5 prior to percutaneous coronary intervention (pre-PCI) versus those who received it after PCI (post-PCI) in the setting of cardiogenic shock (CS) complicating an acute myocardial infarction (AMI). Background Early mechanical circulatory support may improve outcome in the setting of CS complicating an AMI. However, the optimal timing to initiate hemodynamic support has not been well characterized. Methods Data from 154 consecutive patients who underwent PCI and Impella 2.5 support from 38 US hospitals participating in the USpella Registry were included in our study. The primary end-point was survival to discharge. Secondary end-points included assessment of patients' hemodynamics and in-hospital complications. A multivariate regression model was used to identify independent predictors for mortality. Results Both groups were comparable except for diabetes (P = 0.02), peripheral vascular disease (P = 0.008), chronic obstructive pulmonary disease (P = 0.05), and prior stroke (P = 0.04), all of which were more prevalent in the pre-PCI group. Patients in the pre-PCI group had more lesions (P = 0.006) and vessels (P = 0.01) treated. These patients had also significantly better survival to discharge compared to patients in the post-PCI group (65.1% vs.40.7%, P = 0.003). Survival remained favorable for the pre-PCI group after adjusting for potential confounding variables. Initiation of support prior to PCI with Impella 2.5 was an independent predictor of in-hospital survival (Odds ratio 0.37, 95% confidence interval: 0.17-0.79, P = 0.01) in multivariate analysis. The incidence of in-hospital complications included in the secondary end-point was similar between the 2 groups. Conclusions The results of our study suggest that early initiation of hemodynamic support prior to PCI with Impella 2.5 is associated with more complete revascularization and improved survival in the setting of refractory CS complicating an AMI. (J Interven Cardiol 2014;27:1-11) [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
114. Incidence of Early Atrial Fibrillation After Transcatheter versus Surgical Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials.
- Author
-
Altaii, Haider, Morcos, Ramez, Riad, Fady S., Abdulameer, Halah, Khalili, Houman, Maini, Brijeshwar, Lieberman, Eric, Vivas, Yoel, Wiegn, Phi, Joglar, Jose A., Mackall, Judith, Al-Kindi, Sadeer G., and Thal, Sergio
- Subjects
- *
ATRIAL fibrillation , *AORTIC valve transplantation , *RANDOMIZED controlled trials , *RANDOM effects model , *HEART valve prosthesis implantation - Abstract
Background: Post-operative atrial fibrillation (POAF) is common after aortic valve replacement (AVR) and is associated with worse outcomes. We performed a meta-analysis of randomized controlled trials comparing Surgical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) for incidence of POAF at 30 days. Methods: We searched databases from 1/1/1990 to 1/1/2020 for randomized studies comparing TAVR and SAVR. POAF was defined as either worsening or new-onset atrial fibrillation. Random effects model was used to estimate the risk of POAF with TAVR vs SAVR in all trials, and in subgroups (low, intermediate, high risk, and in self-expandable vs balloon expandable valves). Sensitivity analysis was performed including only studies reporting new-onset atrial fibrillation Results: Seven RCTs were identified that enrolled 7,934 patients (3,999 to TAVR and 3,935 to SAVR). The overall incidence of POAF was 9.7% after TAVR and 33.3% after SAVR. TAVR was associated with a lower risk of POAF compared with SAVR (OR 0.21 [0.18-0.24]; P < 0.0001). Compared with SAVR, TAVR was associated with a significantly lower risk of POAF in the high-risk cohort (OR 0.37 [0.27-0.49]; P < 0.0001), in the intermediate-risk cohort (OR 0.23 [0.19-0.28]; P < 0.0001), low-risk cohort (OR 0.13 [0.10-0.16]; P < 0.0001). Sensitivity analysis of 4 trials including only new-onset POAF showed similar summary estimates (OR 0.21, 95% CI [0.18-0.25]; P< 0.0001). Conclusions: TAVR is associated with a significantly lower risk of post-operative atrial fibrillation compared with SAVR in all strata. Further studies are needed to identify the contribution of post-operative atrial fibrillation to the differences in clinical outcomes after TAVR and SAVR. [ABSTRACT FROM AUTHOR]
- Published
- 2020
115. Comparison of Figure-of-Eight Suture and Perclose ProGlide Suture-Mediated Closure in Large Bore Venous Access Hemostasis: A Randomized Controlled Trial.
- Author
-
Lodhi H, Shaukat S, Mathews A, Maini B, and Khalili H
- Subjects
- Humans, Femoral Artery surgery, Hemostasis, Hemostatic Techniques, Suture Techniques, Sutures, Treatment Outcome, Vascular Surgical Procedures, Hemostasis, Surgical methods, Vascular Closure Devices
- Abstract
Suture-mediated closure device and Figure-of-Eight suture are commonly used to achieve hemostasis after use of large bore venous access. Although both methods of closure are commonly used in clinical practice, a head-to-head comparison in a controlled setting has not been performed. Patients presenting to a single center for elective left atrial appendage occlusion or transcatheter edge-to-edge mitral valve repair were randomized to large bore venous closure using the Perclose ProGlide suture-based closure or a Figure-of-Eight suture closure. The patients were followed for 1 month after the procedure. Primary outcome, a composite of access site large ecchymosis, hematoma, infection, pain, need for unscheduled venous ultrasound and need for transfusion, was compared between the 2 arms. A total of 40 patients were randomized in a 1:1 fashion to the 2 venous closure strategies. Baseline characteristics were similar between the 2 groups. Perclose ProGlide arm required use of more devices for hemostasis (1.5 ± 0.5 vs 1 ± 0 respectively, p <0.0001), and there was a significant difference in the cost of closure device ($367.00 ± 122.00 vs $1.00 ± 0 respectively, p <0.001). At 1 month post-procedure, the primary outcome occurred in 4 patients (20%) in the Perclose arm and 7 (35%) patients in the Figure-of-Eight arm, a difference that was not statistically significant (p = 0.48). Time to hemostasis between Figure-of-Eight and Perclose arms did not reach statistical significance (2.5 ± 2.1 vs 3.7 ± 2.3, p = 0.09). In conclusion, both Perclose ProGlide suture-based device and Figure-of-Eight closure are equally feasible and safe for patients who underwent large bore venous access. Figure-of-Eight-based closure is more cost effective., Competing Interests: Declaration of Competing Interest The authors have no competing interests to declare., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
116. Percutaneous Left Atrial Appendage Closure Among Patients With Diabetes (Insights from a National Database).
- Author
-
Hamed M, Morcos R, Elbadawi A, Osman A, Jneid H, Khalife W, Maini B, and Khalili H
- Subjects
- Humans, Retrospective Studies, Hospital Mortality, Treatment Outcome, Atrial Fibrillation complications, Atrial Fibrillation epidemiology, Atrial Fibrillation surgery, Atrial Appendage surgery, Stroke epidemiology, Stroke etiology, Stroke prevention & control, Diabetes Mellitus
- Abstract
Atrial fibrillation is a major risk factor for stroke. Left atrial appendage closure (LAAC) has emerged as an alternative to anticoagulation for patients with high risk of bleeding. Diabetes mellitus (DM) is associated with adverse events after cardiac procedures. We sought to compare procedural and hospital outcomes in patients who underwent LAAC with and without DM. The Nationwide Inpatient Database was queried for patients with atrial fibrillation who underwent LAAC between January 1, 2016, and December 31, 2019. The primary outcome was all adverse events that included in-hospital death, acute myocardial infarction, cardiac arrest, stroke, pericardial effusion, pericardial tamponade, pericardiocentesis, pericardial window, and postprocedural hemorrhage requiring blood transfusion. Analysis included 62,220 patients who underwent LAAC from 2016 to 2019; 34.9% of patients had DM. There was a slight increase in the percentage of patients who underwent LAAC who had DM during the study period, from 29.92% to 34.93%. In unadjusted and adjusted analysis, there was no significant difference in all adverse events between patients with and without DM who underwent LAAC (9.18% vs 8.77%, respectively, adjusted p = 0.63), and no difference in length of stay. Patients with DM have higher risk of acute kidney injury (3.75 vs 1.96%, p <0.001). This nationwide retrospective study demonstrates that DM is not associated with an increase in adverse event rates in patients who underwent LAAC., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
117. Coronary Obstruction From TAVR in Native Aortic Stenosis: Development and Validation of Multivariate Prediction Model.
- Author
-
Khan JM, Kamioka N, Lisko JC, Perdoncin E, Zhang C, Maini A, Chen M, Li Y, Ludwig S, Westermann D, Amat Santos IJ, Kalińczuk Ł, Sinning JM, Kawaguchi T, Fuku Y, Cheema AN, Félix-Oliveira A, Yamamoto M, Kagase A, Codner P, Valle RD, Iyer VS, Kim HS, Lin MS, Maini B, Rodriguez R, Montorfano M, Ancona MB, Tada N, Miyasaka M, Ahmad H, Ruggiero NJ, Torguson R, Ben-Dor I, Shults CC, Weissman G, Lederman RJ, Greenbaum AB, Babaliaros VC, Waksman R, and Rogers T
- Subjects
- Humans, Hospital Mortality, Treatment Outcome, Heart, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Coronary Occlusion
- Abstract
Background: Transcatheter aortic valve replacement (TAVR)-related coronary artery obstruction prediction remains unsatisfactory despite high mortality and novel preventive therapies., Objectives: This study sought to develop a predictive model for TAVR-related coronary obstruction in native aortic stenosis., Methods: Preprocedure computed tomography and fluoroscopy images of patients in whom TAVR caused coronary artery obstruction were collected. Central laboratories made measurements, which were compared with unobstructed patients from a single-center database. A multivariate model was developed and validated against a 1:1 propensity-matched subselection of the unobstructed cohort., Results: Sixty patients with angiographically confirmed coronary obstruction and 1,381 without obstruction were included. In-hospital death was higher in the obstruction cohort (26.7% vs 0.7%; P < 0.001). Annular area and perimeter, coronary height, sinus width, and sinotubular junction height and width were all significantly smaller in the obstructed cohort. Obstruction was most common on the left side (78.3%) and at the level of the coronary artery ostium (92.1%). Coronary artery height and sinus width, but not annulus area, were significant risk factors for obstruction by logistic regression but performed poorly in predicting obstruction. The new multivariate model (coronary obstruction IF cusp height > coronary height, AND virtual valve-to-coronary distance ≤4 mm OR culprit leaflet calcium volume >600 mm
3 ) performed well, with an area under the curve of 0.93 (sensitivity = 0.93, specificity = 0.84) for the left coronary artery and 0.94 (sensitivity = 0.92, specificity = 0.96) for the right., Conclusions: A novel computed tomography-based multivariate prediction model that can be implemented routinely in real-world practice predicted coronary artery obstruction from TAVR in native aortic stenosis., Competing Interests: Funding Support and Author Disclosures This work was supported by a research grant from Medtronic to MedStar Cardiovascular Research Network and MedStar Health. Dr Kamioka has served as a proctor for Edwards Lifesciences. Dr Ludwig has received grant support from the German Heart Foundation; and received travel compensation from Edwards Lifesciences. Dr. Sinning has received speaker honoraria and research grants from Abbott, Abiomed, Medtronic, Boston Scientific, and Edwards Lifesciences; and served as a proctor for Medtronic and Boston Scientific. Dr Fuku has served as a proctor for Edwards Lifesciences and Medtronic. Dr Iyer has served as a proctor for Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Rodriguez has served as a speaker for Medtronic, Abbott, and Edwards Lifesciences. Dr Montorfano has served as a proctor for Edwards Lifesciences, Boston Scientific, and Abbott. Dr Ancona has received consulting fees from Abbott and Abiomed. Dr Ahmad has served as a proctor for Edwards Lifesciences. Dr Ruggiero has served as a proctor for Abbott and Edwards Lifesciences; served as a consultant for Abbott, Edwards Lifesciences, and RegenX-Bio; and received research support from Ancora Heart and Bard. Dr Weissman has served as the director of an academic cardiac computed tomography core lab with institutional contracts with Ancora Heart and LivaNova. Dr Waksman has served on the advisory board for Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, and Pi-Cardia Ltd; has served as a consultant for Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd, Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc, and Venous MedTech; has received institutional grant support from Amgen, Biotronik, Boston Scientific, Chiesi, Medtronic, and Philips IGT; and is an investor in MedAlliance and Transmural Systems Inc. Dr Rogers has served as a proctor and consultant for Boston Scientific, Edwards Lifesciences, and Medtronic; has served on the advisory board for Medtronic; and holds equity interest in Transmural Systems Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
118. Outcomes of the roll-in cohort of the Amulet IDE trial of left atrial appendage occlusion.
- Author
-
Lakkireddy D, Thaler D, Ellis CR, Swarup V, Sondergaard L, Carroll J, Gold MR, Hermiller J, Diener HC, Schmidt B, MacDonald L, Mansour M, Maini B, Anderson JA, Gage R, and Windecker S
- Abstract
Background: Left atrial appendage (LAA) occlusion is an alternative therapy to oral anticoagulants to reduce stroke risk in patients with nonvalvular atrial fibrillation (NVAF). The Amulet IDE trial compared the Amplatzer™ Amulet™ occluder (Abbott) with the Watchman™ 2.5 device (Boston Scientific) for LAA occlusion in patients with NVAF., Objective: The purpose of this study was to describe outcomes of the Amulet IDE trial roll-in cohort., Methods: At US sites up to 3 patients per implanter could be implanted with the Amulet occluder in the roll-in phase. The primary Endpoints in the Amulet IDE trial included safety (composite of procedure-related complications, all-cause death, or major bleeding at 12 months), effectiveness (composite of ischemic stroke or systemic embolism at 18 months), and rate of LAA occlusion at 45 days., Results: A total of 201 roll-in patients were enrolled. Device success occurred in 99% of patients, and device closure (residual jet ≤5 mm) was observed in 98.9% of patients at 45 days. The safety endpoint rate was numerically higher (worse) in the roll-in cohort compared to the randomized Amulet occluder cohort (18.4% vs 14.5%). Six patients (3.1%) experienced an ischemic stroke and 0 patients with a systemic embolism within 18 months, which was similar to the primary effectiveness endpoint rate in the randomized Amulet occluder cohort (2.8%)., Conclusions: Despite lack of experience of the operators with the Amulet occluder in the roll-in phase, device implant success was high, a high rate of device closure was achieved, and low stroke rates were observed in patients with NVAF., (© 2022 Heart Rhythm Society. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
119. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.
- Author
-
Lakkireddy D, Thaler D, Ellis CR, Swarup V, Sondergaard L, Carroll J, Gold MR, Hermiller J, Diener HC, Schmidt B, MacDonald L, Mansour M, Maini B, O'Brien L, and Windecker S
- Subjects
- Aged, Female, Humans, Male, Septal Occluder Device standards, Stroke therapy
- Abstract
Background: Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with nonvalvular atrial fibrillation. The Amulet IDE trial (Amplatzer Amulet Left Atrial Appendage Occluder IDE Trial) was designed to evaluate the safety and effectiveness of the dual-seal mechanism of the Amulet LAA occluder compared with the Watchman device., Methods: Patients with nonvalvular atrial fibrillation at increased risk of stroke were randomly assigned (1:1) to undergo percutaneous implantation of a LAA occluder with the Amulet occluder or Watchman device. The primary end points included safety (composite of procedure-related complications, all-cause death, or major bleeding at 12 months), effectiveness (composite of ischemic stroke or systemic embolism at 18 months), and the rate of LAA occlusion at 45 days. Prespecified secondary end points included a composite of all stroke, systemic embolism, or cardiovascular/unexplained death at 18 months, major bleeding at 18 months, and superiority test of the 3 primary end points., Results: A total of 1878 patients were enrolled. The Amulet occluder was noninferior to the Watchman device for the primary safety end point (14.5% versus 14.7%; difference=-0.14 [95% CI, -3.42 to 3.13]; P <0.001 for noninferiority). Major bleeding and all-cause death were similar between groups (10.6% versus 10.0% and 3.9% versus 5.1%, respectively). Procedure-related complications were higher for the Amulet occluder (4.5% versus 2.5%), largely related to more frequent pericardial effusion and device embolization. The Amulet occluder was noninferior to the Watchman device for the primary effectiveness end point (2.8% versus 2.8%; difference=0.00 [95% CI, -1.55 to 1.55]; P <0.001 for noninferiority), and the composite of stroke, systemic embolism, or cardiovascular/unexplained death (5.6% versus 7.7%, difference=-2.12 [95% CI, -4.45 to 0.21]; P <0.001 for noninferiority). The rate of major bleeding was similar between groups (11.6% versus 12.3%; difference=-0.71 [95% CI, -3.72 to 2.31]; P =0.32 for superiority). LAA occlusion was higher for the Amulet occluder than for the Watchman device (98.9% versus 96.8%; difference=2.03 [95% CI, 0.41-3.66]; P <0.001 for noninferiority; P =0.003 for superiority)., Conclusions: The Amulet occluder was noninferior for safety and effectiveness of stroke prevention for nonvalvular atrial fibrillation compared with the Watchman device and superior for LAA occlusion. Procedure-related complications were higher with the Amulet occluder and decreased with operator experience. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02879448.
- Published
- 2021
- Full Text
- View/download PDF
120. Quality of Life Outcomes After Transcatheter Aortic Valve Replacement in Nonagenarians.
- Author
-
Khalili H, Bansal P, Al Taii H, Morcos R, Kucharik M, Mathews A, Lodhi H, Chandrasekhar S, Fahmy A, Doddapaneni D, and Maini B
- Subjects
- Activities of Daily Living, Age Factors, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve surgery, Female, Health Status, Humans, Male, Quality of Life, Risk Factors, Treatment Outcome, Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis surgery, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: Transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) is an increasingly prevalent treatment in patients who are intermediate or high risk for surgical intervention. In nonagenarian patients undergoing TAVR, symptomatic relief and quality of life (QoL) outcomes have not been well established. This study explores these outcomes in this patient population that has been underrepresented in landmark clinical trials., Methods: All patients who underwent TAVR between January 1, 2015 and December 31, 2018 at Delray Medical Center were included. The 12-item Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score was used to assess QoL prior to and 30 days following TAVR in two patient groups: the nonagenarian group (patients ≥90 years old) and the younger group (patients <90 years old). KCCQ-OS scores were compared between these two groups. Frailty assessment included grip strength, gait speed, and activities of daily living. Unadjusted and adjusted analyses (baseline KCCQ-OS score, frailty, and Society of Thoracic Surgery perioperative risk of mortality [STS-PROM] score) were performed to assess the impact of age on QoL outcomes in both groups., Results: Of the total 223 patients included in this study, a total of 46 (20.6%) were nonagenarians and 118 (52.7%) were men. KCCQ-OS scores were lower at baseline and 30-day follow-up in nonagenarians compared with the younger group (P=.70). Age was a significant predictor of 30- day KCCQ-OS in unadjusted and adjusted analyses (adjusted for baseline KCCQ-OS, frailty, and STS-PROM score). Nonagenarians had an average 6.45 points lower 30-day KCCQ-OS scores than the younger patients in adjusted analysis. However, there was a significant clinical improvement in the 30-day KCCQ-OS score in both groups (P<.001)., Conclusions: Our data suggest that with appropriate patient selection, a significant clinical improvement may be expected with TAVR in nonagenarians.
- Published
- 2020
121. 2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques.
- Author
-
Yamamoto MH, Maehara A, Stone GW, Kini AS, Brilakis ES, Rizik DG, Shunk K, Powers ER, Tobis JM, Maini BS, Dixon SR, Goldstein JA, Petersen JL 2nd, Généreux P, Shah PR, Crowley A, Nicholls SJ, Mintz GS, Muller JE, and Weisz G
- Subjects
- Aged, Drug-Eluting Stents adverse effects, Female, Follow-Up Studies, Humans, Lipid Metabolism physiology, Male, Middle Aged, Percutaneous Coronary Intervention adverse effects, Prospective Studies, Registries, Spectroscopy, Near-Infrared trends, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease metabolism, Drug-Eluting Stents trends, Percutaneous Coronary Intervention trends, Plaque, Atherosclerotic diagnostic imaging, Plaque, Atherosclerotic metabolism
- Abstract
Background: Autopsy studies suggest that implanting stents in lipid-rich plaque (LRP) may be associated with adverse outcomes., Objectives: The purpose of this study was to evaluate the association between LRP detected by near-infrared spectroscopy (NIRS) and clinical outcomes in patients with coronary artery disease treated with contemporary drug-eluting stents., Methods: In this prospective, multicenter registry, NIRS was performed in patients undergoing coronary angiography and possible percutaneous coronary intervention (PCI). Lipid core burden index (LCBI) was calculated as the fraction of pixels with the probability of LRP >0.6 within a region of interest. MaxLCBI
4mm was defined as the maximum LCBI within any 4-mm-long segment. Major adverse cardiac events (MACE) included cardiac death, myocardial infarction, definite or probable stent thrombosis, or unplanned revascularization or rehospitalization for progressive angina or unstable angina. Events were subcategorized as culprit (treated) lesion-related, nonculprit (untreated) lesion-related, or indeterminate., Results: Among 1,999 patients who were enrolled in the COLOR (Chemometric Observations of Lipid Core Plaques of Interest in Native Coronary Arteries Registry), PCI was performed in 1,621 patients and MACE occurred in 18.0% of patients, of which 8.3% were culprit lesion-related, 10.7% were nonculprit lesion-related, and 3.1% were indeterminate during 2-year follow-up. Complications from NIRS imaging occurred in 9 patients (0.45%), which resulted in 1 peri-procedural myocardial infarction and 1 emergent coronary bypass. Pre-PCI NIRS imaging was obtained in 1,189 patients, and the 2-year rate of culprit lesion-related MACE was not significantly associated with maxLCBI4mm (hazard ratio of maxLCBI4mm per 100: 1.06; 95% confidence interval: 0.96 to 1.17; p = 0.28) after adjusting clinical and procedural factors., Conclusions: Following PCI with contemporary drug-eluting stents, stent implantation in NIRS-defined LRPs was not associated with increased periprocedural or late adverse outcomes compared with those without significant lipid., (Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
122. Comparison of Outcomes of Percutaneous Coronary Intervention on Native Coronary Arteries Versus on Saphenous Venous Aorta Coronary Conduits in Patients With Low Left Ventricular Ejection Fraction and Impella Device Implantation Achieved or Attempted (from the PROTECT II Randomized Trial and the cVAD Registry).
- Author
-
Shavelle DM, Banerjee S, Maini B, Schreiber TL, Kapasi N, O'Neill WW, Popma J, and Matthews RV
- Subjects
- Aged, Biomarkers blood, Comorbidity, Coronary Artery Disease mortality, Female, Humans, Male, Prospective Studies, Registries, Reoperation, Stroke Volume, Survival Rate, Treatment Outcome, Ventricular Dysfunction, Left mortality, Coronary Artery Bypass adverse effects, Coronary Artery Disease surgery, Coronary Vessels transplantation, Heart-Assist Devices, Percutaneous Coronary Intervention, Saphenous Vein transplantation, Ventricular Dysfunction, Left physiopathology
- Abstract
Patients with prior coronary artery bypass grafting (CABG) represent a high-risk cohort given associated medical conditions and worse outcome of saphenous vein graft compared with native vessel percutaneous coronary intervention (PCI). The goal of the current analysis was to compare clinical outcomes in 591 patients with and without prior CABG and multivessel coronary artery disease or unprotected left main disease and severely reduced left ventricular systolic function underwent Impella supported PCI from the PROTECT II randomized trial and the cVAD Registry. Patients with prior CABG surgery (n = 201) were compared with those without prior CABG surgery (n = 390). The primary end point of this analysis was overall mortality at 30 days. Patients with prior CABG surgery had greater Society of Thoracic Surgery mortality score compared with patients without prior CABG surgery, 7.6 ± 6.4 versus 5.1 ± 5.5, respectively, p <0.001. Saphenous vein graft PCI was performed in 17% of patients with prior CABG surgery. Number of vessels treated was lower in patients with prior CABG surgery compared with patients without prior CABG surgery, 1.66 ± 0.56 versus 1.89 ± 0.64, respectively, p <0.001. Achievement of TIMI 3 flow post PCI and overall PCI success was similar in the two groups. Overall mortality at 30 days was similar in patients with prior CABG surgery compared with patients without prior CABG surgery, 6.75% versus 6.61%, respectively, p = 1.0. In conclusion, in this high-risk cohort of patients underwent hemodynamically supported PCI, prior CABG surgery was not associated with worse outcome. The use of hemodynamic support appears to mitigate the increased risk of PCI associated with prior CABG., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
123. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.
- Author
-
Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, and Gurley JC
- Subjects
- Adult, Double-Blind Method, Echocardiography, Doppler methods, Female, Humans, Male, Middle Aged, Pain Management methods, Pain Measurement methods, Severity of Illness Index, Treatment Outcome, Cardiac Catheterization methods, Foramen Ovale, Patent complications, Foramen Ovale, Patent diagnosis, Foramen Ovale, Patent surgery, Migraine Disorders complications, Migraine Disorders diagnosis, Migraine Disorders physiopathology, Migraine Disorders therapy, Prosthesis Implantation adverse effects, Prosthesis Implantation instrumentation, Prosthesis Implantation methods, Septal Occluder Device
- Abstract
Background: Migraine is a prevalent and disabling disorder. Patent foramen ovale (PFO) has been associated with migraine, but its role in the disorder remains poorly understood., Objectives: This study examined the efficacy of percutaneous PFO closure as a therapy for migraine with or without aura., Methods: The PREMIUM (Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management) was a double-blind study investigating migraine characteristics over 1 year in subjects randomized to medical therapy with a sham procedure (right heart catheterization) versus medical therapy and PFO closure with the Amplatzer PFO Occluder device (St. Jude Medical, St. Paul, Minnesota). Subjects had 6 to 14 days of migraine per month, had failed at least 3 migraine preventive medications, and had significant right-to-left shunt defined by transcranial Doppler. Primary endpoints were responder rate defined as 50% reduction in migraine attacks and adverse events. Secondary endpoints included reduction in migraine days and efficacy in patients with versus without aura., Results: Of 1,653 subjects consented, 230 were enrolled. There was no difference in responder rate in the PFO closure (45 of 117) versus control (33 of 103) groups. One serious adverse event (transient atrial fibrillation) occurred in 205 subjects who underwent PFO closure. Subjects in the PFO closure group had a significantly greater reduction in headache days (-3.4 vs. -2.0 days/month, p = 0.025). Complete migraine remission for 1 year occurred in 10 patients (8.5%) in the treatment group versus 1 (1%) in the control group (p = 0.01)., Conclusions: PFO closure did not meet the primary endpoint of reduction in responder rate in patients with frequent migraine. (Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management [PREMIUM]; NCT00355056)., (Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
124. One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease.
- Author
-
O'Hair DP, Bajwa TK, Chetcuti SJ, Deeb GM, Stoler RC, Hebeler RF, Maini B, Mumtaz M, Kleiman NS, Reardon MJ, Li S, Adams DH, Watson DR, Yakubov SJ, Popma JJ, and Petrossian G
- Subjects
- Aged, Aged, 80 and over, Aortic Valve Stenosis diagnostic imaging, Cause of Death, Comorbidity, Echocardiography, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Kidney Failure, Chronic diagnostic imaging, Male, Postoperative Complications diagnostic imaging, Prospective Studies, Renal Replacement Therapy, Risk Factors, Survival Rate, Aortic Valve Stenosis mortality, Aortic Valve Stenosis surgery, Kidney Failure, Chronic complications, Postoperative Complications mortality, Transcatheter Aortic Valve Replacement methods, Transcatheter Aortic Valve Replacement mortality
- Abstract
Background: End-stage renal disease (ESRD) poses unique challenges in the treatment of patients with severe aortic stenosis. Although surgical valve replacement in ESRD patients has been associated with increased mortality, the outcomes from transcatheter aortic valve replacement (TAVR) are not clearly defined., Methods: The CoreValve US Expanded Use Study is a prospective, nonrandomized study of TAVR in extreme-risk patients with comorbidities excluding them from the Pivotal Trial. We report on patients with ESRD. The primary endpoint was a composite of all-cause mortality or major stroke at 1 year., Results: Ninety-six patients with ESRD underwent TAVR with the CoreValve (Medtronic, Minneapolis, MN) and have reached 1-year follow-up. Mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 16.2% ± 8.4%. The rate of all-cause mortality or major stroke at 1 year was 30.3%. The all-cause mortality rate was 5.3% at 30 days and 30.3% at 1 year. The rate at 1 year of any stroke or transient ischemic attack was 2.1%; major vascular injury was 5.2%; and new permanent pacemaker was 26.8%. Valve performance improved postprocedure and remained improved at 1 year (effective orifice area 1.71 cm
2 , mean gradient 9.33 mm Hg) CONCLUSIONS: Early mortality in patients with ESRD is comparable to previously published data on extreme-risk patients without ESRD, but our data suggest a higher mortality rate at 1 year for ESRD patients, likely due to comorbid conditions. Stroke and major vascular injury are infrequent, and improved valve hemodynamics are maintained at 1 year., (Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
125. Effect of Early Initiation of Mechanical Circulatory Support on Survival in Cardiogenic Shock.
- Author
-
Basir MB, Schreiber TL, Grines CL, Dixon SR, Moses JW, Maini BS, Khandelwal AK, Ohman EM, and O'Neill WW
- Subjects
- Aged, Female, Hemodynamics, Humans, Male, Middle Aged, Registries, Risk Factors, Shock, Cardiogenic mortality, Survival Rate, Treatment Outcome, Heart-Assist Devices, Shock, Cardiogenic therapy
- Abstract
The role and timing of percutaneous mechanical circulatory support (MCS) devices in the treatment of acute myocardial infarction complicated by cardiogenic shock (AMICS) are not well understood. We sought to evaluate patient characteristics and predictors of outcomes in patients presenting with AMICS supported with an axial flow percutaneous MCS device; 287 consecutive unselected patients enrolled in the catheter-based ventricular assist device registry presenting with AMICS who underwent percutaneous coronary intervention (PCI) were included in this analysis. All patients were supported with either the Impella 2.5 or Impella CP. Mean patient age was 66 ± 12.5 years, 76% were men, and mean left ventricular ejection fraction was 25 ± 12%. Before receiving MCS, 80% of patients required inotropes or vasopressors and 40% were supported with intra-aortic balloon pump; 9% of patients were under active cardiopulmonary resuscitation at the time of MCS implantation. Survival to discharge was 44%. In a multivariate analysis, early implantation of a MCS device before PCI (p = 0.04) and before requiring inotropes and vasopressors (p = 0.05) was associated with increased survival. Survival was 66% when MCS was initiated <1.25 hours from shock onset, 37% when initiated within 1.25 to 4.25 hours, and 26% when initiated after 4.25 hours (p = 0.017). Survival was 68%, 46%, 35%, 35%, and 26% for patients requiring 0, 1, 2, 3, and ≥4 inotropes before MCS support, respectively (p <0.001). In conclusion, MCS implantation early after shock onset, before initiation of inotropes or vasopressors and before PCI, is independently associated with improved survival in patients presenting with AMICS., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
126. Real-time three-dimensional intracardiac echocardiography: an early single-center experience.
- Author
-
Maini B
- Subjects
- Humans, Inventions, Monitoring, Intraoperative methods, Perioperative Care methods, Cardiac Surgical Procedures adverse effects, Cardiac Surgical Procedures methods, Echocardiography, Three-Dimensional methods, Echocardiography, Three-Dimensional trends, Echocardiography, Transesophageal methods, Echocardiography, Transesophageal trends, Heart Diseases diagnosis, Heart Diseases surgery, Postoperative Complications prevention & control
- Abstract
As interventional procedures in structural heart diseases are coming of age, there is a significant lag in the periinterventional imaging development for these procedures to become safe, expedient, accurate, and well tolerated by this patient population. Currently, transesophageal echocardiography (TEE), including real-time three-dimensional (RT-3D), has been used for monitoring and guidance for these procedures. Accurate identification of the pathology, its anatomy, and its relationship with the adjoining structures along with spatial resolution is of paramount importance for wire and catheter placement, device deployment, evaluation of the results, and any potential complications. Two-dimensional intracardiac echocardiography (ICE) has been used extensively for a variety of interventional procedures that undergo conscious sedation of monitored anesthesia. RT-3D ICE has recently become available; we describe our initial experience with this new imaging technology.
- Published
- 2015
127. In vivo lipid core plaque modification with percutaneous coronary revascularization: a near-infrared spectroscopy study.
- Author
-
Maini A, Buyantseva L, and Maini B
- Subjects
- Algorithms, Biomarkers, Female, Follow-Up Studies, Humans, Lipids analysis, Male, Myocardial Infarction epidemiology, Plaque, Atherosclerotic chemistry, Risk Factors, Treatment Outcome, Troponin metabolism, Coronary Artery Disease metabolism, Coronary Artery Disease therapy, Lipid Metabolism physiology, Percutaneous Coronary Intervention, Plaque, Atherosclerotic metabolism, Spectroscopy, Near-Infrared
- Abstract
Background: Coronary revascularization is associated with no-reflow phenomenon and elevation of cardiac biomarkers. This may occur due to plaque modification. We used near-infrared spectroscopy (NIRS) to evaluate lipid core plaque (LCP) modification with coronary revascularization and its correlation with periprocedural myocardial infarction., Methods: Patients presenting to the cardiac catheterization laboratory who underwent NIRS, NIRS/intravascular ultrasound (IVUS) were reviewed and their lipid core burden index (LCBI) was assessed. Using fuzzy c-means clustering algorithm, the coronary was divided into three zones and the lipid burden was recalculated. Its correlation to postprocedure troponin elevation and outcomes with a mean follow-up of 42 months were studied., Results: A total of 77 coronaries were evaluated. There was an overall decrease in the LCBI after percutaneous revascularization (P<.0001). Using fuzzy c-means clustering algorithm, there was always a decrease in the lipid burden at the site of the percutaneous revascularization (P<.0001). Postprocedure troponin elevation was only noted in patients with an axial shifting of the LCP. There was no difference in long-term outcomes due to the degree of reduction of lipid burden or its axial., Conclusions: Plaque modification may be performed successfully using interventional methods and can be evaluated with NIRS. Axial plaque shifting is an acute prognostic marker for postprocedure myocardial infarction.
- Published
- 2013
128. A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention.
- Author
-
Gregory D, Scotti DJ, de Lissovoy G, Palacios I, Dixon S, Maini B, and O'Neill W
- Abstract
Background: The economic burden of heart disease is heavy and growing. As advanced technologies for treating heart disease become available, decision makers need to be able to assess the relative value of such options against existing standards of care., Objectives: To compare the clinical and economic benefits of a percutaneous ventricular assist device (pVAD) versus an intra-aortic balloon pump (IABP) observed during the 90-day duration of the PROTECT II clinical trial, and to supplement these findings with a simulation of the longer-term value of this technology through the use of a Markov model to estimate the incremental cost-effectiveness of a pVAD relative to an IABP, in terms of quality-adjusted life-years (QALYs)., Methods: Hospital bills were collected for patients enrolled in the PROTECT II trial who received hemodynamic support for high-risk percutaneous coronary intervention (PCI) provided by a pVAD (Impella 2.5) versus a conventional IABP during a 90-day episode of care (EOC). Length of stay, charges, and costs were analyzed for the index admissions, intensive care unit confinements, readmissions, and overall EOC. In addition, a probabilistic Markov model was used to project these parameters and their impact on a patient's quality of life for up to 10 years in relation to a pVAD versus an IABP., Results: Hospital costs for the index admission were lower for the IABP compared with the pVAD ($33,684 vs $47,667; P <.001), whereas readmission length of stay and costs were lower for the pVAD versus the IABP (5 days vs 7 days; and $11,007 vs $21,834, respectively; P <.001). The total 90-day hospital charges were similar for the pVAD and the IABP ($172,564 vs $172,758, respectively; P = .785); however, the total 90-day EOC cost was lower for the IABP than for the pVAD ($44,032 vs $53,171, respectively; P <.001). The median hospital days for the entire EOC were 7 days for the pVAD versus 9 days for the IABP (P = .008). Critical care stays were considerably shorter for a pVAD than for an IABP on readmissions (3.88 days vs 7.00 days; P = .145). Reduction in major adverse cardiovascular and cerebrovascular events resulted in a projected gain of 0.26 QALYs over 10 years, yielding an incremental cost-effectiveness ratio of $39,389/QALY., Conclusions: For high-risk patients with advanced heart failure undergoing PCI, the new pVAD reduced major adverse events, critical care and readmission length of stay, and readmission cost over the 90-day EOC, and was determined to be cost-effective over the long-term. These findings can assist decision makers in forming value-based judgments with regard to new hemodynamic support strategies.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.